

**Question for written answer E-001764/2025
to the Commission**

Rule 144

Jaume Asens Llodrà (Verts/ALE), Danilo Della Valle (The Left), Mimmo Lucano (The Left), Özlem Demirel (The Left), Vladimir Prebilič (Verts/ALE), Rima Hassan (The Left), Fernando Barrena Arza (The Left), Marc Botenga (The Left), Dario Tamburrano (The Left), Leila Chaibi (The Left), Rudi Kennes (The Left), Carolina Morace (The Left), João Oliveira (The Left)

Subject: Health cooperation with Cuba

1. Does the Commission plan to urge the European Medicines Agency (EMA) to review treatments and vaccines developed by the Cuban public health system, such as Heberprot-P or CIMAvax-EGF, using scientific – not political – criteria, with the aim of ensuring access to effective and affordable medicines for the European population?
2. Does the Commission consider that the US economic embargo on Cuba justifies the EU's passivity in health cooperation, even when that blockade goes against the principles of sovereignty, global justice and the right to health that the EU claims to uphold?
3. Is the Commission planning to include a specific line of cooperation in medical biotechnology, health research, knowledge and technology transfer as a coherent way of protecting the right to health and the health autonomy of the Global South?

Submitted: 30.4.2025